NewLimit has raised an additional $45M from Lilly, Duke University, Section 32, & Abstract on a $1.62B cap

Five months after closing our Series B, NewLimit has raised an additional $45M from Eli Lilly and Company, Duke Management Co, Section 32, and others on a $1.62B cap. Insiders including Kleiner Perkins, Dimension, Abstract, Human Capital, and Boost also participated. This round was propelled by new technical breakthroughs following our Series B that set the stage for our first clinical study in a few years.

NewLimit is developing medicines that can restore youthful function in old cells through epigenetic reprogramming. Since our Series B, we’ve already seen significant advances in our lead programs that give us the confidence to start planning clinical studies in the near term.

At NewLimit, we are firm believers that a new class of longevity medicines can improve the lives of everyone on the planet, even those not diagnosed with classically defined disease. We appreciate each of these new capital partners joining to support our mission.